Tagged with Opinion,

Global Taking the massive Microsoft acquisition of videogame company Activision Blizzard as his jumping-off point, Shawview Consulting’s Brendan Shaw lays out six key life science industry trends to watch in the coming year and wonders whether 2022 will be pharma’s ‘Call of Duty’ moment.   A few weeks ago, 2022 started…

APAC Drawing on the findings of a recent report launched under the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some of the key trends that emerged from report, conducted…

Global Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some of Astellas’ work with patient advocacy groups to generate these insights, why a new era of real-world data (RWD) generation…

Australia Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how artificial intelligence (AI) solutions can best be applied to pharmacovigilance in Australia, and the challenges that stand ahead.   For…

China PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of COVID-19 vaccines in China.   Since the breakout of COVID-19, many pharmaceutical companies in China have worked to develop preventative…

South Africa Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions, the vital importance of health innovation in and for Africa, the potential impact of a new partnership with global pharma…

Global David H. Crean summarizes the recent 40th annual J.P. Morgan Healthcare Conference 2022 that was held in a virtual format. Crean underlines the importance of the Conference for establishing the tone and tenor for the industry and highlights some of the biopharma topics to monitor.   39 years ago, JPM launched…

Global 2021 saw PharmaBoardroom’s network of executives and experts weighing in on some of the most pressing issues facing our industry today. See below for five of the most thought-provoking pieces, ranging from patient engagement to access solutions, infrastructure building, biomarkers, and sustainability.   A ‘Bold Vision’ of Patient Engagement The…

Europe Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA system in Europe and the objectives of the recently launched EUnetHTA 21 initiative.   Global Forum recently published a piece on Health Technology Assessment (HTA) in the EU and how a regulation…

Singapore Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for orphan drug registration in four ASEAN countries and what more could be done to improve it.   Regulatory authorities such…

Global David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal activities and financings over the past two years since his original article on the topic was published on PharmaBoardroom in June 2019.   Cell and gene…

Global PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca and the EU, the skills that pharma leaders need in the MEA region, the year’s most prominent trends, and how…